tiprankstipranks
Trending News
More News >
GE Healthcare Technologies Inc (GEHC)
NASDAQ:GEHC
Advertisement

GE Healthcare Technologies Inc (GEHC) AI Stock Analysis

Compare
1,698 Followers

Top Page

GEHC

GE Healthcare Technologies Inc

(NASDAQ:GEHC)

Select Model
Select Model
Select Model
Outperform 74 (OpenAI - 4o)
Rating:74Outperform
Price Target:
$84.00
▲(9.88% Upside)
GE Healthcare Technologies Inc. demonstrates strong financial performance and a positive outlook from the latest earnings call, despite facing cash flow challenges and tariff impacts. The technical indicators suggest a neutral trend, while the valuation appears fair. The company's strategic initiatives and raised guidance contribute positively to the overall score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.
Strategic Partnerships
Strategic partnerships enhance product offerings and market reach, fostering innovation and sustained revenue streams.
Cash Generation
Strong cash generation supports financial stability and investment in growth opportunities, ensuring long-term viability.
Negative Factors
Tariff Impacts
Tariff impacts can erode profit margins, affecting financial performance and competitiveness over the long term.
Patient Care Solutions Challenges
Challenges in key segments can hinder overall growth and require strategic adjustments to regain momentum.
Decline in Free Cash Flow
A decline in free cash flow may indicate inefficiencies in cash management, impacting future investment capacity and financial health.

GE Healthcare Technologies Inc (GEHC) vs. SPDR S&P 500 ETF (SPY)

GE Healthcare Technologies Inc Business Overview & Revenue Model

Company DescriptionGE Healthcare Technologies Inc (GEHC) is a leading global medical technology and digital solutions innovator, primarily focused on improving patient outcomes and enhancing operational efficiency in healthcare. The company operates in several sectors, including imaging, monitoring, biomanufacturing, and diagnostics. GEHC's core products and services encompass advanced imaging equipment such as MRI and CT scanners, ultrasound systems, patient monitoring solutions, and healthcare IT software, all aimed at providing healthcare professionals with critical insights and tools for better patient care.
How the Company Makes MoneyGE Healthcare generates revenue through multiple streams, primarily by selling medical imaging equipment, patient monitoring systems, and diagnostic tools to healthcare institutions worldwide. The company also earns significant income from software solutions and services, including digital health platforms that facilitate data management and analytics for healthcare providers. Additionally, GEHC benefits from long-term service agreements and maintenance contracts, which provide ongoing revenue through repairs, upgrades, and technical support for installed equipment. Strategic partnerships with hospitals, research institutions, and technology firms further enhance its market reach and contribute to its earnings by enabling collaborative innovations and expanding its product offerings.

GE Healthcare Technologies Inc Key Performance Indicators (KPIs)

Any
Any
Remaining Performance Obligations by Type
Remaining Performance Obligations by Type
Represents the value of contracted work yet to be completed, indicating future revenue streams and the company's ability to secure long-term commitments.
Chart InsightsGE Healthcare's services segment is showing robust growth, driven by strategic collaborations and successful new product introductions, contributing to a record backlog. Despite challenges from tariffs impacting margins, the company remains optimistic, raising its full-year guidance. The products segment, however, faces headwinds, with a slight decline in obligations, possibly due to slower recovery in key markets like China. Investors should note the strong services momentum and strategic initiatives that could offset product-related pressures.
Data provided by:Main Street Data

GE Healthcare Technologies Inc Earnings Call Summary

Earnings Call Date:Oct 29, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 02, 2026
Earnings Call Sentiment Positive
The earnings call reflected a strong performance in revenue growth, strategic partnerships, and successful segments like Pharmaceutical Diagnostics. However, challenges such as tariffs impacting margins and issues in the Patient Care Solutions segment were noted. Despite these challenges, the company raised its adjusted EPS guidance, indicating a positive outlook.
Q3-2025 Updates
Positive Updates
Strong Organic Revenue Growth
GE Healthcare reported a 4% organic revenue growth year-over-year, driven by solid customer demand and robust orders growth of 6% across all segments.
Significant Backlog and Order Growth
The company exited the quarter with a backlog of $21.2 billion, with a strong book-to-bill ratio of 1.06x and trailing four-quarter orders growth at 6%.
Successful Strategic Partnerships
Partnerships such as the 14-year Care Alliance with UC San Diego Health and the planned acquisition of icometrix highlight strategic initiatives to strengthen product portfolios and drive growth.
Impressive Performance in Pharmaceutical Diagnostics
The Pharmaceutical Diagnostics segment delivered a 10% organic sales growth year-over-year, with a 14% EBIT growth.
Raised Adjusted EPS Guidance
Due to strong performance year-to-date, GE Healthcare raised its adjusted EPS guidance for the full year, reflecting confidence in future performance.
Negative Updates
Impact of Tariffs on Margins
Adjusted EBIT margin was affected by tariffs, leading to a 150 basis points decline year-over-year, highlighting a $95 million tariff impact in the quarter.
Patient Care Solutions Segment Challenges
Organic revenue in the Patient Care Solutions segment was down 7% due to a product hold, resulting in a 680 basis points decline in EBIT margin year-over-year.
Decline in Adjusted EPS
Adjusted EPS was down 6% year-over-year, primarily due to the impact of tariffs, though it would have been up in the high single digits excluding this impact.
Company Guidance
In the GE Healthcare Third Quarter 2025 Earnings Conference Call, the company reported a 4% organic revenue growth and a 6% increase in orders, reflecting strong demand across all segments. The backlog stood at $21.2 billion, highlighting customer investment in GE's new products and solutions. Adjusted EBIT margin was 14.8%, down 150 basis points year-over-year, largely due to a $95 million tariff impact. Adjusted EPS was $1.07, down 6% year-over-year, but excluding tariff impacts, it would have increased in the high single digits. Free cash flow was $483 million, with a 99% conversion rate. GE Healthcare raised its adjusted EPS guidance for the year, projecting between $4.51 and $4.63 per share. The company highlighted significant R&D investments, leading to innovations in diagnostic imaging and AI-enabled solutions, and expressed confidence in achieving mid-single-digit organic growth in the medium term.

GE Healthcare Technologies Inc Financial Statement Overview

Summary
GE Healthcare Technologies Inc. shows strong revenue growth and profitability with significant improvements in leverage and return on equity. However, challenges in cash flow generation could impact liquidity, necessitating a focus on cost management and cash flow improvement.
Income Statement
85
Very Positive
GE Healthcare Technologies Inc. demonstrates strong revenue growth with a TTM increase of 1.4%, indicating a positive trajectory. The company maintains healthy profitability with a gross profit margin of 40.8% and a net profit margin of 10.9% in the TTM. EBIT and EBITDA margins are also robust at 15.9% and 18.8% respectively, reflecting efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.
Balance Sheet
78
Positive
The balance sheet shows a significant improvement in leverage, with a TTM debt-to-equity ratio of 0.20, down from 1.11 the previous year, indicating reduced financial risk. The return on equity remains strong at 23.7%, showcasing effective use of equity. However, the equity ratio is not explicitly calculated, and the decrease in stockholders' equity over the years could be a concern for long-term stability.
Cash Flow
65
Positive
Cash flow analysis reveals challenges with a significant decline in free cash flow growth by 70.4% in the TTM, indicating potential liquidity issues. The operating cash flow to net income ratio is low at 0.09, suggesting that cash generation from operations is not keeping pace with net income. However, the free cash flow to net income ratio remains healthy at 50.7%, indicating some level of cash flow efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue20.25B19.67B19.55B18.34B17.59B17.16B
Gross Profit8.26B8.21B7.92B7.18B7.17B6.77B
EBITDA3.80B3.67B3.51B3.17B3.54B3.41B
Net Income2.22B1.99B1.57B1.92B2.25B13.85B
Balance Sheet
Total Assets36.13B33.09B32.45B27.54B26.31B24.23B
Cash, Cash Equivalents and Short-Term Investments4.00B2.89B2.50B1.45B556.00M1.01B
Total Debt10.74B9.38B9.86B8.63B437.00M468.00M
Total Liabilities25.91B24.44B25.14B17.95B9.41B9.25B
Stockholders Equity9.99B8.45B7.13B9.36B16.66B14.73B
Cash Flow
Free Cash Flow463.00M1.55B1.71B1.80B1.36B1.43B
Operating Cash Flow913.00M1.95B2.10B2.11B1.61B1.69B
Investing Cash Flow-1.02B-914.00M-558.00M-398.00M-1.76B19.99B
Financing Cash Flow-367.00M-573.00M-478.00M-822.00M-263.00M-21.54B

GE Healthcare Technologies Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price76.45
Price Trends
50DMA
74.68
Positive
100DMA
74.57
Positive
200DMA
75.05
Positive
Market Momentum
MACD
-0.36
Negative
RSI
57.23
Neutral
STOCH
72.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Positive. The current price of 76.45 is above the 20-day moving average (MA) of 74.54, above the 50-day MA of 74.68, and above the 200-day MA of 75.05, indicating a bullish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 57.23 is Neutral, neither overbought nor oversold. The STOCH value of 72.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GEHC.

GE Healthcare Technologies Inc Risk Analysis

GE Healthcare Technologies Inc disclosed 33 risk factors in its most recent earnings report. GE Healthcare Technologies Inc reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

GE Healthcare Technologies Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$8.78B61.696.78%15.45%37.72%
74
Outperform
$34.82B15.8124.22%0.18%3.52%32.21%
72
Outperform
$9.49B40.2224.61%20.21%44.14%
66
Neutral
$40.00B47.4213.72%15.96%27.91%
64
Neutral
$3.59B50.67%-578.00%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
$12.51B-72.61%72.58%76.81%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GEHC
GE Healthcare Technologies Inc
76.45
-6.06
-7.34%
VEEV
Veeva Systems
244.06
17.11
7.54%
HQY
Healthequity
101.91
-1.85
-1.78%
DOCS
Doximity
50.42
1.67
3.43%
TEM
Tempus AI, Inc. Class A
70.29
6.40
10.02%
HNGE
Hinge Health, Inc. Class A
45.99
5.83
14.52%

GE Healthcare Technologies Inc Corporate Events

GE Healthcare’s Earnings Call: Growth Amid Challenges
Oct 31, 2025

The recent earnings call of GE Healthcare Technologies Inc. painted a picture of robust performance despite some challenges. The general sentiment was positive, with the company showcasing strong revenue growth and strategic partnerships, particularly in the Pharmaceutical Diagnostics segment. However, issues such as tariffs affecting margins and challenges in the Patient Care Solutions segment were also highlighted. Nevertheless, the company’s decision to raise its adjusted EPS guidance suggests a confident outlook for the future.

GE HealthCare Reports Robust Q3 2025 Growth
Oct 30, 2025

GE HealthCare Technologies Inc. is a leading global provider of healthcare solutions, specializing in medical technology, pharmaceutical diagnostics, and AI-enabled services, aimed at enhancing the efficiency of healthcare systems and improving patient outcomes.

GE HealthCare Reports Strong Q2 2025 Performance
Jul 31, 2025

GE HealthCare Technologies Inc., a leader in the healthcare sector, specializes in medical technology, pharmaceutical diagnostics, and AI-enabled solutions, aiming to enhance patient care and healthcare system efficiency. In its latest earnings report for the second quarter of 2025, GE HealthCare announced a 3% increase in revenue year-over-year, with a notable rise in net income margin to 9.7% from 8.9% the previous year. The company also reported a significant improvement in cash flow from operating activities, reaching $94 million compared to a negative $119 million in the prior year.

GE Healthcare’s Earnings Call Highlights Growth Amid Challenges
Jul 31, 2025

The recent earnings call for GE Healthcare Technologies Inc. painted a picture of robust growth and strategic achievements, albeit with some challenges. The overall sentiment was positive, driven by strong order growth and an optimistic financial outlook, particularly in the Imaging and Nuclear Medicine sectors. However, the company faces hurdles such as tariff impacts, difficulties in the China market, and stagnant performance in Patient Care Solutions, which have put pressure on margins.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 31, 2025